Literature DB >> 28283778

PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.

Julia Alejandra Pezuk1,2, María Sol Brassesco3, Ricardo Santos de Oliveira4, Hélio Rubens Machado4, Luciano Neder5, Carlos Alberto Scrideli6, Luiz Gonzaga Tone6.   

Abstract

PURPOSE: Medulloblastoma (MB) is the most common malignant tumor of the central nervous system (CNS) in children. Despite its relative good survival rates, treatment can cause long time sequels and may impair patients' lifespan and quality, making the search for new treatment options still necessary. Polo like kinases (PLKs) constitute a five-member serine/threonine kinases family (PLK 1-5) that regulates different stages during cell cycle. Abnormal PLKs expression has been observed in several cancer types, including MB. As gene regulators, miRNAs have also been described with variable expression in cancer.
METHODS: We evaluated gene expression profiles of all PLK family members and related miRNAs (miR-100, miR-126, miR-219, and miR-593*) in MB cell lines and tumor samples.
RESULTS: RT-qPCR analysis revealed increased levels of PLK1-4 in all cell lines and in most MB samples, while PLK5 was found underexpressed. In parallel, miR-100 was also found upregulated while miR-129, miR-216, and miR-593* were decreased in MB cell lines. Variable miRNAs expression patterns were observed in MB samples. However, a correlation between miR-100 and PLK4 expression was observed, and associations between miR-100, miR-126, and miR-219 expression and overall and event free survival were also evinced in our cohort. Moreover, despite the lack of association with clinico-pathological features, when comparing primary tumors to those relapsed, we found a consistent decrease on PLK2, miR-219, and miR-598* and an increase on miR-100 and miR-126.
CONCLUSION: Specific dysregulation on PLKs and associated miRNAs may be important in MB and can be used to predict prognosis. Although miRNAs sequences are fundamental to predict its target, the cell type may also be consider once that mRNA repertoire can define different roles for specific miRNA in a given cell.

Entities:  

Keywords:  Medulloblastoma; PLKs; miR-100; miR-126; miR-217; miR-593*

Mesh:

Substances:

Year:  2017        PMID: 28283778     DOI: 10.1007/s00381-017-3366-5

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  42 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Polo-like kinases: conservation and divergence in their functions and regulation.

Authors:  Vincent Archambault; David M Glover
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04       Impact factor: 94.444

3.  Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.

Authors:  Joanna Triscott; Cathy Lee; Colleen Foster; Branavan Manoranjan; Mary Rose Pambid; Rachel Berns; Abbas Fotovati; Chitra Venugopal; Katrina O'Halloran; Aru Narendran; Cynthia Hawkins; Vijay Ramaswamy; Eric Bouffet; Michael D Taylor; Ash Singhal; Juliette Hukin; Rod Rassekh; Stephen Yip; Paul Northcott; Sheila K Singh; Christopher Dunham; Sandra E Dunn
Journal:  Cancer Res       Date:  2013-09-09       Impact factor: 12.701

Review 4.  Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues.

Authors:  Jeffrey A Winkles; Gregory F Alberts
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

5.  Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines.

Authors:  Tewarit Sarachana; Rulun Zhou; Guang Chen; Husseini K Manji; Valerie W Hu
Journal:  Genome Med       Date:  2010-04-07       Impact factor: 11.117

6.  Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.

Authors:  Eric F Johnson; Kent D Stewart; Keith W Woods; Vincent L Giranda; Yan Luo
Journal:  Biochemistry       Date:  2007-07-27       Impact factor: 3.162

7.  MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines.

Authors:  M Crawford; E Brawner; K Batte; L Yu; M G Hunter; G A Otterson; G Nuovo; C B Marsh; S P Nana-Sinkam
Journal:  Biochem Biophys Res Commun       Date:  2008-07-03       Impact factor: 3.575

8.  Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions.

Authors:  Yali Yang; Jingxiang Bai; Rulong Shen; Sharron A N Brown; Elena Komissarova; Ying Huang; Ning Jiang; Gregory F Alberts; Max Costa; Luo Lu; Jeffrey A Winkles; Wei Dai
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

Review 9.  From Plk1 to Plk5: functional evolution of polo-like kinases.

Authors:  Guillermo de Cárcer; Gerard Manning; Marcos Malumbres
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

Review 10.  Molecular Classification of Medulloblastoma.

Authors:  Noriyuki Kijima; Yonehiro Kanemura
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-05-26       Impact factor: 1.742

View more
  4 in total

1.  Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.

Authors:  Masanori Kawakami; Lisa Maria Mustachio; Lin Zheng; Yulong Chen; Jaime Rodriguez-Canales; Barbara Mino; Jonathan M Kurie; Jason Roszik; Pamela Andrea Villalobos; Kelsie L Thu; Jennifer Silvester; David W Cescon; Ignacio I Wistuba; Tak W Mak; Xi Liu; Ethan Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-06       Impact factor: 11.205

2.  The polo-like kinase 4 gene (PLK4) is overexpressed in pediatric medulloblastoma.

Authors:  Simone Treiger Sredni; Tadanori Tomita
Journal:  Childs Nerv Syst       Date:  2017-05-11       Impact factor: 1.475

3.  Identification of microRNA signature in different pediatric brain tumors.

Authors:  Marwa Tantawy; Mariam G Elzayat; Dina Yehia; Hala Taha
Journal:  Genet Mol Biol       Date:  2018-03-26       Impact factor: 1.771

Review 4.  The Non-coding Side of Medulloblastoma.

Authors:  Pietro Laneve; Elisa Caffarelli
Journal:  Front Cell Dev Biol       Date:  2020-05-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.